04 — Regulatory Affairs Company
Pharmaceutical Regulatory Affairs Company.
OutcomePartners receive a submission-ready dossier and a team that answers the reviewer’s questions on it.
- Dossiers in preparation in our own portfolio
- 24V-20
- Dossiers in preparation in our own portfolio
- Plus rest-of-world markets
- US · EU
- Plus rest-of-world markets
- Dossier models: develop or compile
- 2
- Dossier models: develop or compile
01
Regulatory strategyV-19
Strategy decides the development route before the laboratory work begins: which reference product, which legal pathway, which markets, and what evidence each of them will demand. Our differentiated portfolio is built on non-infringing and 505(b)(2)-style routes chosen this way.
02
Documentation and dossiers
We develop the dossier alongside the product, or compile one from a partner’s existing development data. Programme management at KMS covers dossier development for regulators including the US FDA.
03
Submission support and query resolution
Analytical and formulation sections are written by the people who generated the data, and the same team answers deficiency letters and reviewer questions. Responses are faster and more defensible when the authors are still on the programme.
04
Market-specific requirements
Programmes and dossiers are prepared for the United States, Europe and rest-of-world markets, each with its own expectations for stability, impurities and documentation.
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · ganesan@kmshc.com · +91 97898 75194V-23